

Special Issue

Pancreatic Ductal Adenocarcinoma: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

Pancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide. The dismal prognosis of PC patients is attributable to the strong propensity of the disease to disseminate at an early stage. Thus, at the time of diagnosis, only 20% of PC patients are eligible for surgical resection. Furthermore, resistance to chemotherapy and radiotherapy contributes to the high mortality rates registered in PC patients. This Special Issue will provide insights regarding the molecular pathogenesis of PC and how the molecular driver of PC cells could be targeted. Authors are invited to submit their original research, communications, and review articles to *Biomedicines*. Potential topics include but not limited to:

- The role of cancer stem cells or tumor-initiating cells in the genesis and progression of PC;
- Genetic changes and gene expression patterns associated with PC subtypes;
- The impact of the epigenetic changes in PC;
- The contribution of tumor stroma in the PC;
- Potential biomarkers for predicting the progression and response to therapy of PC;
- The immuno-oncology approaches in PC;
- Antistroma therapies in PC;
- Role of the exosomes in PC.

Guest Editor

Dr. Rossano Lattanzio

Center for Advanced Studies and Technology (CAST), Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio" Chieti-Pescara, 66100 Chieti, Italy

Deadline for manuscript submissions

closed (31 January 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/33731

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).